Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA grants breakthrough therapy status to crizanlizumab

pharmaceutical-technologyJanuary 10, 2019

Tag: FDA , Breakthrough Therapy , crizanlizumab , Novartis

PharmaSources Customer Service